Back to Search Start Over

AstraZeneca reports Fasenra approved in China for severe eosinophilic asthma

Source :
The Fly. August 20, 2024
Publication Year :
2024

Abstract

AstraZeneca's Fasenra has been approved in China by the country's National Medical Products Association, or NMPA, for the maintenance treatment of patients 12 years of age and older with severe [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
The Fly
Publication Type :
Periodical
Accession number :
edsgcl.805493089